Moderna, Inc. (NASDAQ:MRNA) Stock Has Consensus Target Price of $101.45

Key Points

• Analyst consensus is “Hold”: Four of 25 brokerages rate Moderna a sell, 14 recommend holding, and seven recommend buying. The average 12-month price target is $101.45, although several analysts recently raised their targets or upgraded the stock.
• Moderna shares have surged: The stock opened at $226.89, up 4.1%, near its 52-week high of $242.29. The company remains unprofitable, reporting a quarterly loss of $1.97 per share despite revenue exceeding expectations.
• Insider selling contrasts with institutional buying: Company insiders sold $33.9 million of stock over the past 90 days, while institutional investors own 75.33% of Moderna and major firms including BlackRock and Theleme Partners initiated significant positions.

Shares of Moderna, Inc. (NASDAQ:MRNA - Get Free Report) have received an average rating of "Hold" from the twenty-five brokerages that are currently covering the stock, MarketBeat Ratings reports. Four research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and seven have issued a buy rating on the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $101.45.

Several research analysts recently weighed in on MRNA shares. CLSA upgraded shares of Moderna to an "outperform" rating in a research report on Friday, August 28th. Bradesco Corretora raised Moderna to an "outperform" rating in a report on Friday, August 28th. Jefferies Financial Group reiterated a "hold" rating and issued a $150.00 price objective (up from $60.00) on shares of Moderna in a research report on Wednesday, August 19th. Evercore increased their price objective on Moderna from $50.00 to $80.00 in a research report on Thursday, October 8th. Finally, UBS Group reissued a "neutral" rating on shares of Moderna in a research note on Tuesday, September 22nd.

Insider Activity

In other news, CFO Jamey Mock sold 34,836 shares of the company's stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer owned 59,375 shares of the company's stock, valued at $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Stephen Hoge sold 40,294 shares of the firm's stock in a transaction dated Monday, September 14th. The shares were sold at an average price of $144.13, for a total value of $5,807,574.22. Following the completion of the transaction, the president owned 1,525,858 shares in the company, valued at approximately $219,921,913.54. This represents a 2.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 197,251 shares of company stock valued at $33,875,904 over the last 90 days. 10.80% of the stock is owned by company insiders.

Institutional Trading of Moderna

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in Moderna during the 2nd quarter worth approximately $2,142,877,000. Theleme Partners LLP bought a new position in Moderna in the second quarter valued at approximately $564,272,000. Wellington Management Group LLP boosted its holdings in shares of Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company's stock valued at $172,384,000 after buying an additional 103,977 shares during the period. First Trust Advisors LP boosted its holdings in shares of Moderna by 59.3% in the first quarter. First Trust Advisors LP now owns 2,392,693 shares of the company's stock valued at $121,549,000 after buying an additional 891,072 shares during the period. Finally, Merck & Co. Inc. acquired a new position in shares of Moderna in the second quarter valued at approximately $161,642,545. 75.33% of the stock is owned by institutional investors.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Higher price targets: Oddo BHF raised its Moderna price target to $251 from $170, following a broader improvement in sentiment toward the company’s pipeline. BofA also recently increased its target, reinforcing the bullish outlook. Oddo BHF Adjusts Moderna Price Target to $251 From $170
• Positive Sentiment: Investors are positioning ahead of melanoma data: Moderna is expected to provide detailed Phase 3 data this Saturday for its personalized cancer vaccine, developed with Merck. Favorable results could strengthen the case for a major oncology growth opportunity beyond COVID-19 vaccines. What's Going On With Moderna Stock Monday?
• Positive Sentiment: Upcoming ESMO visibility: Merck/Moderna’s oncology program is among the key topics expected to attract attention at ESMO 2026, potentially increasing investor focus on Moderna’s cancer pipeline and clinical catalysts. Merck/Moderna, Summit/Akeso and ADCs to headline ESMO 2026
• Positive Sentiment: Index inclusion and AI-driven healthcare theme: Moderna’s addition to the Nasdaq-100 may support institutional demand and visibility. Separately, analysts are highlighting the company as a potential beneficiary of “biointelligence,” including data-driven drug development and personalized therapies. Moderna Just Joined the Nasdaq-100. Here's What That Means for Investors.
• Neutral Sentiment: Biotech sector interest: Moderna appeared on a broader list of biotech stocks to watch, but the item provided no major company-specific development. Biotech Stocks To Watch Now - October 15th
• Negative Sentiment: Insider selling: Moderna’s president sold roughly $8.4 million and $8.6 million worth of shares in separate reported transactions. The sales may weigh on sentiment, particularly after an earlier report linked insider selling to a sharp decline in the stock. Moderna President Sells $8,373,539.52 in Stock Insider Selling: Moderna President Sells $8,640,084.40 in Stock

Moderna Trading Up 4.1%

Shares of NASDAQ MRNA opened at $226.89 on Tuesday. Moderna has a 1-year low of $22.28 and a 1-year high of $242.29. The company has a 50-day moving average of $160.00 and a two-hundred day moving average of $92.42. The company has a market cap of $90.58 billion, a PE ratio of -28.40 and a beta of 1.09. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA - Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) EPS for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million for the quarter, compared to analysts' expectations of $102.93 million. During the same period in the prior year, the firm earned ($2.13) earnings per share. Moderna's revenue was up 2.1% compared to the same quarter last year. As a group, equities analysts expect that Moderna will post -6.11 earnings per share for the current fiscal year.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company's research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna's commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.